Log in to save to my catalogue

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS a...

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS a...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2389387298

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations

About this item

Full title

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations

Publisher

Cold Spring Harbor: Cold Spring Harbor Laboratory Press

Journal title

bioRxiv, 2020-04

Language

English

Formats

Publication information

Publisher

Cold Spring Harbor: Cold Spring Harbor Laboratory Press

More information

Scope and Contents

Contents

In non−small cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and the tumor suppressor STK11 encoding the kinase LKB1 result in aggressive tumors prone to metastasis but with liabilities arising from reprogrammed metabolism. We previously demonstrated perturbed nitrogen metabolism and addiction to an unconventional pathway of pyr...

Alternative Titles

Full title

The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2389387298

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2389387298

Other Identifiers

E-ISSN

2692-8205

DOI

10.1101/2020.04.13.039669